---
layout: default
title: Cobicistat
parent: 僅模型預測 (L5)
nav_order: 106
evidence_level: L5
indication_count: 3
---

# Cobicistat
{: .fs-9 }

證據等級: **L5** | 預測適應症: **3** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cobicistat: From Undocumented Original Indication to Feline Acquired Immunodeficiency Syndrome (Signal)

## One-Sentence Summary

The evidence pack for cobicistat (DB09065) does not contain a documented original indication or mechanism of action, and the drug is currently **not marketed in Germany**. The TxGNN model's top prediction is **Feline Acquired Immunodeficiency Syndrome**, but this signal is currently supported by **0 clinical trials** and **0 publications**, making it a model-only prediction with no external validation.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no licensed indication text in the evidence pack |
| Predicted New Indication | Feline Acquired Immunodeficiency Syndrome |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for cobicistat in this evidence pack, and no original indication is documented either. This makes it impossible to formally assess mechanistic plausibility for the predicted indication at this time.

That said, the top two TxGNN predictions — feline acquired immunodeficiency syndrome (rank 1) and simian immunodeficiency virus infection (rank 2) — share a notable pattern: both are lentiviral immunodeficiency diseases in animal species, structurally and pathophysiologically analogous to human HIV/AIDS. This clustering suggests the model may be capturing a genuine antiviral or immunodeficiency-related signal in the knowledge graph rather than pure noise. However, without MOA data, original indication data, or any supporting trials/literature, this remains an unconfirmed hypothesis rather than an evidence-backed rationale.

A third, lower-ranked prediction in the pack (a rare neurodevelopmental disorder, evidence level L5, decision S0/Hold) was explicitly flagged as having no identifiable mechanistic link and was assessed as likely embedding noise — reinforcing that not all TxGNN outputs for this drug carry equal biological plausibility, and rank 1/2 warrant independent verification rather than automatic trust.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Germany Market Information

Cobicistat is currently not marketed in Germany, and no authorization records are available in the evidence pack.

---

## Safety Considerations

Please refer to the package insert for safety information.

*Note: Package insert warnings and contraindications for this drug are currently a blocking data gap (DG001) — this must be resolved before any safety evaluation can proceed.*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No clinical trials, literature, mechanism of action, or original indication data support this prediction, and the drug is unmarketed in Germany. Package insert safety data is a blocking gap. Evidence is insufficient to advance beyond a raw model signal.

**To proceed, the following is needed:**
- Original indication and MOA data (e.g., via DrugBank API query)
- TFDA/BfArM package insert warnings and contraindications (resolves blocking gap DG001)
- Targeted literature/trial search on cobicistat in HIV/lentivirus-related repurposing contexts, to test the FIV/SIV mechanistic hypothesis
- Clarification on why a feline-specific veterinary disease appears as the top-ranked prediction, and whether a human-relevant analog indication should be substituted
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

